The NanoCind ® signature is an independent prognosticator of recurrence and death in uterine leiomyosarcomas.

CONCLUSIONS: The NanoCind® signature is a powerful prognosticator that outperforms FIGO staging and the genomic index. The CINSARC signature is platform-independent and "ready to use" and should now be used for randomization in future therapeutic trials.
PMID: 31796515 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - December 2, 2019 Category: Cancer & Oncology Authors: Croce S, Lesluyes T, Valle C, M'Hamdi L, Thébault N, Pérot G, Stoeckle E, Noël JC, Fontanges Q, Devouassoux-Shisheboran M, Querleu D, Guyon F, Floquet A, CHakiba C, Mayeur L, Rebier F, MacGrogan G, Soubeyran I, Le Guellec S, Chibon F Tags: Clin Cancer Res Source Type: research